← Back to Clinical Trials
Recruiting NCT06860425

NCT06860425 Use of a Comprehensive, Mobile Application to Assist Cancer Patients With Diet, Nutrition and Activity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06860425
Status Recruiting
Phase
Sponsor Montefiore Medical Center
Condition Mobile Applications
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2023-02-28
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
RestoreMe

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2023-02-28 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overarching purpose of this study is to assess whether patients will use the app throughout treatment on a regular basis, as the ultimate goal is to provide an educational platform that can impact patient behaviors and understanding towards health.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of invasive malignancy of the brain, head and neck region, lung, breast (DCIS and invasive disease allowed), prostate, gastrointestinal system or gynecological region * Planned to receive, or have received, radiation therapy treatment with curative intent * Note: Patients undergoing systemic therapy are eligible * Note: Any dose/fractionation of curative-intent radiation therapy is eligible * Patients must have a smartphone or other device with the ability to receive text messages, download and use mobile applications * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Ability to read and write in English * Provide written informed consent to participate in the study o NOTE: Patients enrolled on another clinical trial are eligible Exclusion Criteria: * Metastatic cancer * Undergoing treatment with palliative intent * Poorly controlled diabetes (defined as fasting glucose level \> 200 mg/dL despite attempts to improve glucose control by fasting duration and adjustment of medications) * Uncontrolled hypertension * Any medical condition requiring fluid restriction or nutrient restrictions

Contact & Investigator

Central Contact

Rafi Kabarriti, MD

✉ rkabarri@montefiore.org

📞 914-629-7743

Principal Investigator

Rafi Kabarriti, MD

PRINCIPAL INVESTIGATOR

Montefiore Medical Center

Frequently Asked Questions

Who can join the NCT06860425 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mobile Applications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06860425 currently recruiting?

Yes, NCT06860425 is actively recruiting participants. Contact the research team at rkabarri@montefiore.org for enrollment information.

Where is the NCT06860425 trial being conducted?

This trial is being conducted at The Bronx, United States.

Who is sponsoring the NCT06860425 clinical trial?

NCT06860425 is sponsored by Montefiore Medical Center. The principal investigator is Rafi Kabarriti, MD at Montefiore Medical Center. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology